Generally speaking, immune checkpoint inhibitors (ICIs), for example, mAbs against PD-1 or PD-L1, or some other ICIs, have shown disappointing results in DLBCL [529]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.